You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

5-HT1A Receptors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Atypical Antipsychotics inGeriatric Population: What is Role of

Recruiting
  • Neutropenia
    • Strasbourg, France
      Service de Pharmacie - Stérilisation - CHU de Strasbourg - Franc
    Oct 27, 2023

    Breast Cancer, Chemo-induced Nausea and Vomiting Trial in Hanzhou (Aprepitant, Palonosetron, Fosaprepitant)

    Not yet recruiting
    • Breast Cancer
    • Chemotherapy-induced Nausea and Vomiting
    • Hanzhou, Zhejiang, China
      the Second Affiliated Hospital of Zhejiang Univercity School of
    Apr 23, 2023

    Implication of 5-HT7 Receptor in Inflammatory Mechanisms in

    Not yet recruiting
    • Healthy
    • Multiple Sclerosis
    • Blood sample
    • Orléans, France
      CHR Orléans
    Feb 16, 2023

    Chemo-induced Nausea and Vomiting Trial in Chengdu (5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone)

    Recruiting
    • Chemotherapy-induced Nausea and Vomiting
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Mar 27, 2023

    Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia Trial (HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5%

    Not yet recruiting
    • Acneiform Eruption Due to Chemical
    • +2 more
    • HT-001 2% Topical Gel
    • +3 more
    • (no location specified)
    Dec 3, 2022

    Complement C5a Receptors in Hidradenitis Suppurativa

    Recruiting
    • Hidradenitis Suppurativa
      • Redwood City, California
        Stanford University
      Jun 27, 2022

      Fragile X Syndrome (FXS) Trial in Stanford (18F-FTC-146)

      Withdrawn
      • Fragile X Syndrome (FXS)
      • Stanford, California
        Stanford University
      Nov 10, 2022

      Exploration of Cluster Headache in a PET-MRI Study

      Not yet recruiting
      • Cluster Headache, Episodic
      • PET-MRI in pain-free remission period
      • (no location specified)
      Oct 18, 2021

      Opioid Use Disorder Trial (CVL-354, [11C]-LY2795050, [11C]-carfentanil)

      Not yet recruiting
      • Opioid Use Disorder
      • New Haven, Connecticut
        New Haven, Connecticut
      Jan 18, 2023

      Tobacco Use Disorder Trial (Psilocybin, Niacin)

      Not yet recruiting
      • Tobacco Use Disorder
      • (no location specified)
      Jul 7, 2022

      Schizophrenia Trial in Boston (CVL-231)

      Recruiting
      • Schizophrenia
      • Boston, Massachusetts
        Massachusetts General Hospital Translational and Clinical Resear
      Jul 6, 2022

      Acute Respiratory Distress Syndrome Trial in Montréal (Placebo, Ondansetron Injection)

      Not yet recruiting
      • Acute Respiratory Distress Syndrome
      • Placebo
      • Ondansetron Injection
      • Montréal, Quebec, Canada
        Hôpital Sacré-Coeur de Montréal
      Aug 22, 2022

      Oropharyngeal Dysphagia, Dysphagia, Swallowing Disorder Trial in Mataró (Capsaicin 10microM (TRPV1 natural agonist), Piperine

      Completed
      • Oropharyngeal Dysphagia
      • +2 more
      • Capsaicin 10microM (TRPV1 natural agonist)
      • +5 more
      • Mataró, Barcelona, Spain
        Consorci Sanitari del Maresme (Hospital de Mataró)
      Jul 12, 2022

      Adverse Effect Trial (normal saline, Ondansetron 4 mg, Ondansetron 8 mg)

      Not yet recruiting
      • Adverse Effect
      • normal saline
      • +2 more
      • (no location specified)
      Jul 25, 2022

      Parkinson Disease Trial in Toulouse (Clinical assessment, Pain characteristics assessment, MRI)

      Not yet recruiting
      • Parkinson Disease
      • Clinical assessment
      • +5 more
      • Toulouse, Haute-Garonne, France
        Centre Hospitalier Universitaire de Toulouse
      Aug 22, 2023

      MDD Trial in London (MIJ821)

      Not yet recruiting
      • Major Depressive Disorder
      • London, United Kingdom
        Parexel Early Phase Clinical Unit (LONDON)
      Dec 18, 2022

      Normal Healthy Subjects Trial in Fair Lawn (HT-6184, HT-6184 Placebo)

      Recruiting
      • Normal Healthy Subjects
      • Fair Lawn, New Jersey
        TKL Research, Inc.
      Jul 6, 2022

      Tobacco Use Disorder, Tobacco Smoking Trial in Baltimore ([F18]-ASEM

      Recruiting
      • Tobacco Use Disorder
      • Tobacco Smoking
      • [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
      • Contingency Management
      • Baltimore, Maryland
        Johns Hopkins Behavioral Pharmacology Research Unit
      Jun 7, 2022

      Chemo-induced Nausea and Vomiting Trial in Zhuhai (Olanzapine+NK-1 RA+5-HT3 RA, Dexamethasone+NK-1 RA+5-HT3 RA)

      Recruiting
      • Chemotherapy-induced Nausea and Vomiting
      • Olanzapine+NK-1 RA+5-HT3 RA
      • Dexamethasone+NK-1 RA+5-HT3 RA
      • Zhuhai, Guangdong, China
        Fifth Affilliated Hospital of Sun Yat-sen University
      May 17, 2021

      Alcohol Use Disorder Trial in Pittsburgh ([C-11], NOP-1A)

      Completed
      • Alcohol Use Disorder
      • Pittsburgh, Pennsylvania
        University of PIttsburgh PET Facility
      Jul 8, 2022

      Healthy Trial in Basel (Placebo, Mescaline 100mg, Mescaline 200mg)

      Recruiting
      • Healthy
      • Placebo
      • +5 more
      • Basel, BS, Switzerland
        University Hospital Basel, Clinical Trial Unit
      Aug 17, 2021

      Chemo-induced Nausea and Vomiting Trial in Worldwide (NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1

      Recruiting
      • Chemotherapy-induced Nausea and Vomiting
      • NEPA (300mg netupitant/0.5mg palonosetron)
      • +2 more
      • Prague, Czechia
      • +12 more
      Nov 8, 2022

      COPD, Interstitial Lung Disease, Heart Failure Trial in Montreal (Honeywell HT-900 Turbo Force Air Circulator)

      Not yet recruiting
      • Chronic Obstructive Pulmonary Disease
      • +2 more
      • Honeywell HT-900 Turbo Force Air Circulator
      • Montreal, Quebec, Canada
        Centre of Innovative Medicine of the McGill University Health Ce
      Dec 12, 2022

      Bipolar Disorder Trial in London (JNJ-18038683, Placebo)

      Recruiting
      • Bipolar Disorder
      • London, United Kingdom
        King's College London
      Sep 6, 2021

      COPD, Interstitial Lung Disease, Heart Failure Trial in Montreal (Honeywell HT-900 Turbo Force Air Circulator)

      Not yet recruiting
      • Chronic Obstructive Pulmonary Disease
      • +2 more
      • Honeywell HT-900 Turbo Force Air Circulator
      • Montreal, Quebec, Canada
        Centre of Innovative Medicine of the McGill University Health Ce
      Dec 12, 2022